Clinical trial NCT04226014: Observational Cohort of Pancreatic Echo-endoscopy
Official title: Score of Echogenicity and Pancreatic Echo-endoscopy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Metabolic Syndrome
Obesity
Hepatic Steatosis
Keywords: pancreatic echogenecity
Hepatic Steatosis
Metabolic Syndrome
Obesity
Lead sponsor: Centre Hospitalier Saint Joseph Saint Luc de Lyon
Sponsor class: OTHER
Collaborators: name: Clinique du Val d'ouest
First posted: 2020-01-13
Enrollment: 97
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Any patient receiving a high echo-endography meeting the inclusion criteria will be included.

Brief summary: Metabolic syndrome is defined by the presence of at least two of the following five criteria: abdominal perimeter\> 94 cm in men, 80 cm in women, high triglycerides, low HDL cholesterol, HTA and hyperglycemia.

The metabolic syndrome can lead to ultrasound hepatic steatosis in 20 to 40% of cases depending on the population studied (overweight vs obesity). What is the impact of this syndrome on pancreatic echogenicity?

Detailed description: Little is known about the pathogenesis of the fatty pancreas. Fat can replace acinar cells and / or pancreatic endocrine cells (1). To date, there are no biomarkers allowing the detection of a fatty pancreas. It appears that older age, male, obesity, alcohol consumption, high triglycerides, high ALT, diabetes or insulin resistance, fatty liver and metabolic syndrome are risk factors for a fatty pancreas (2,3,4).To the investigator's knowledge, these different factors have not been evaluated on the impact of pancreatic echogenecity in endosonography. The objective of this study is to correlate the factors making up the metabolic syndrome with pancreatic echogenecity.

Eligibility criteria: Inclusion Criteria:

* any consecutive patient, having a high echo-endoscopy
* for an extra pancreatic cause, such as the search for a cholelithiasis, (the pancreas will be studied completely)
* for esophageal pathologies, (the pancreas will be studied completely)
* for gastric pathologies, (the pancreas will be studied completely)
* for cystic lesions of the pancreas (pancreas studied upstream and downstream)
* for submucosal tumors (esophageal / gastric / duodenal)
* for abdominal pain of undetermined origin

Exclusion Criteria:

* Patients with pancreatic and / or tissue damage with dilated wirsung canal and / or acute or chronic pancreatitis.
* Patients having contraindication to general anesthesia

Primary outcomes:
measure: Correlation of the pancreatic echogenicity by endoscopic ultrasound with the metabolic syndrome
timeFrame: During the reading of the echo-endoscopic procedure
Secondary outcomes:
measure: Comparaison of the echogenicity of the pancreas with respect to the liver and to the spleen will be made.
timeFrame: During the reading of the echo-endoscopic procedure
Other outcomes:
Locations:
city: Arnas
country: France
facility: Polyclinique du Beaujolais
city: Lyon
country: France
facility: Hôpital privé Jean Mermoz
city: Paris
country: France
facility: Clinique du Trocadéro
city: Vénissieux
country: France
facility: Clinique des Portes du Sud
city: Écully
country: France
facility: Clinique du Val d'Ouest
Study officials:
affiliation: Clinique du Val d'ouest
name: Anne-Marie MARION-AUDIBERT, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: